Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines.
chemotherapy resistance
nucleolar stress
nucleostemin
ovarian cancer
quinacrine
ribosomal biogenesis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Sep 2021
16 Sep 2021
Historique:
received:
08
07
2021
revised:
03
09
2021
accepted:
10
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
A considerable subset of gynecologic cancer patients experience disease recurrence or acquired resistance, which contributes to high mortality rates in ovarian cancer (OC). Our prior studies showed that quinacrine (QC), an antimalarial drug, enhanced chemotherapy sensitivity in treatment-refractory OC cells, including artificially generated chemoresistant and high-grade serous OC cells. In this study, we investigated QC-induced transcriptomic changes to uncover its cytotoxic mechanisms of action. Isogenic pairs of OC cells generated to be chemoresistant and their chemosensitive counterparts were treated with QC followed by RNA-seq analysis. Validation of selected expression results and database comparison analyses indicated the ribosomal biogenesis (RBG) pathway is inhibited by QC. RBG is commonly upregulated in cancer cells and is emerging as a drug target. We found that QC attenuates the in vitro and in vivo expression of nucleostemin (NS/GNL3), a nucleolar RBG and DNA repair protein, and the RPA194 catalytic subunit of Pol I that results in RBG inhibition and nucleolar stress. QC promotes the redistribution of fibrillarin in the form of extranuclear foci and nucleolar caps, an indicator of nucleolar stress conditions. In addition, we found that QC-induced downregulation of NS disrupted homologous recombination repair both by reducing NS protein levels and PARylation resulting in reduced RAD51 recruitment to DNA damage. Our data suggest that QC inhibits RBG and this inhibition promotes DNA damage by directly downregulating the NS-RAD51 interaction. Additionally, QC showed strong synergy with PARP inhibitors in OC cells. Overall, we found that QC downregulates the RBG pathway, induces nucleolar stress, supports the increase of DNA damage, and sensitizes cells to PARP inhibition, which supports new therapeutic stratagems for treatment-refractory OC. Our work offers support for targeting RBG in OC and determines NS to be a novel target for QC.
Identifiants
pubmed: 34572872
pii: cancers13184645
doi: 10.3390/cancers13184645
pmc: PMC8466834
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : U.S. Department of Defense
ID : W81XWH-14-OCRP-IIRA OC140298
Références
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
J Pathol. 2000 Jun;191(2):181-6
pubmed: 10861579
Blood Cancer J. 2015 Apr 17;5:e307
pubmed: 25885427
Onco Targets Ther. 2016 Sep 29;9:5985-5997
pubmed: 27729807
Mol Cell Biol. 2000 Aug;20(16):5930-8
pubmed: 10913176
Mol Oncol. 2016 Dec;10(10):1559-1574
pubmed: 27729194
Genes Dev. 2004 Feb 15;18(4):423-34
pubmed: 15004009
Br J Cancer. 1997;75(11):1593-600
pubmed: 9184173
Cancer Res. 2011 Feb 15;71(4):1418-30
pubmed: 21159662
Oncogene. 2019 May;38(20):3919-3931
pubmed: 30692636
Mol Cell. 2010 Oct 22;40(2):216-27
pubmed: 20965417
Oncogene. 2021 Feb;40(8):1409-1424
pubmed: 33420377
FEBS Lett. 2014 Aug 19;588(16):2571-9
pubmed: 24747423
Oncotarget. 2015 Nov 3;6(34):36354-69
pubmed: 26497553
Cancers (Basel). 2021 Apr 21;13(9):
pubmed: 33919392
Nat Rev Cancer. 2018 Jan;18(1):51-63
pubmed: 29192214
Oncogene. 1999 Jan 28;18(4):1119-24
pubmed: 10023689
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2013 Feb 15;288(7):4567-82
pubmed: 23293027
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Methods Enzymol. 2006;409:524-40
pubmed: 16793422
Cancer Cell. 2012 Jul 10;22(1):51-65
pubmed: 22789538
J Biol Chem. 2010 Apr 16;285(16):12416-25
pubmed: 20159984
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11415-20
pubmed: 23798389
Nat Commun. 2016 Apr 29;7:11457
pubmed: 27126896
Oncotarget. 2015 Oct 27;6(33):34846-58
pubmed: 26472108
Sci Rep. 2018 Feb 6;8(1):2487
pubmed: 29410485
Biochim Biophys Acta. 2014 Jun;1842(6):817-30
pubmed: 24514102
Cancer Biol Ther. 2011 Aug 1;12(3):239-51
pubmed: 21725213
J Biol Chem. 2009 Feb 20;284(8):4968-77
pubmed: 19106111
Cancer Cell. 2014 Jan 13;25(1):77-90
pubmed: 24434211
Cell Cycle. 2007 Jan 1;6(1):11-5
pubmed: 17245116
J Biol Chem. 2010 Apr 16;285(16):12011-27
pubmed: 20154083
Annu Rev Pharmacol Toxicol. 2010;50:131-56
pubmed: 20055700
Oncogene. 2006 Oct 16;25(48):6384-91
pubmed: 17041624
Mol Cancer. 2008 Jan 25;7:15
pubmed: 18221536
Arch Pharm Res. 2001 Apr;24(2):126-35
pubmed: 11339632
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53
pubmed: 16287968
Nat Commun. 2017 Feb 17;8:14432
pubmed: 28211448
Cancer Res. 2013 Jun 15;73(12):3683-91
pubmed: 23548269
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671574
Cancer Inform. 2007 Feb 04;3:11-7
pubmed: 19455231
Cancers (Basel). 2019 Sep 25;11(10):
pubmed: 31557908
Nat Cell Biol. 2005 Mar;7(3):303-10
pubmed: 15723053
Oncogene. 2019 Apr;38(15):2800-2813
pubmed: 30542116
Genes Dev. 2006 Aug 1;20(15):2030-40
pubmed: 16882981
Int J Cancer. 2012 Apr 1;130(7):1660-70
pubmed: 21544805
Front Pharmacol. 2018 Jan 11;8:970
pubmed: 29375377
Oncogene. 2007 Jul 26;26(34):4969-78
pubmed: 17310998
Semin Cancer Biol. 2021 Jan;68:21-30
pubmed: 31562955
Cancer Invest. 2019;37(6):242-252
pubmed: 31296070
Curr Cancer Drug Targets. 2011 Feb;11(2):226-35
pubmed: 21158717
Mol Oncol. 2017 May;11(5):491-516
pubmed: 28236660
Cell Commun Signal. 2011 May 15;9:13
pubmed: 21569639
Mol Biol Cell. 2005 May;16(5):2395-413
pubmed: 15758027
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Neuro Oncol. 2013 Dec;15(12):1673-83
pubmed: 24092859
Cell Stress. 2018 May 10;2(6):125-140
pubmed: 31225478
Future Oncol. 2009 Dec;5(10):1685-704
pubmed: 20001804
Oncotarget. 2017 Dec 8;9(1):1041-1047
pubmed: 29416675